Repatha (Evolocumab) in Pregnancy and Lactation: Safety Evidence and Clinical Guidance

How Evolocumab Works: The PCSK9 Pathway

Evolocumab is a fully human IgG2 monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease produced mainly by the liver 1. PCSK9 normally tags LDL receptors on hepatocyte surfaces for lysosomal degradation. When evolocumab blocks that interaction, LDL receptors recycle back to the cell surface and clear more LDL-C from the bloodstream.

The result is substantial. In the FOURIER trial (N=27,564), evolocumab added to statin therapy reduced LDL-C by a median of 59%, from 92 mg/dL to 30 mg/dL, and cut the composite MACE endpoint by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) over a median 2.2 years of follow-up 1. That trial enrolled patients with established atherosclerotic cardiovascular disease (ASCVD). It excluded pregnant or lactating individuals.

Understanding the mechanism matters here for a specific reason. Because evolocumab is an IgG2 antibody (not a small molecule), it does not freely cross cell membranes. Its placental and breast milk transfer profiles differ from those of statins or ezetimibe. These pharmacokinetic differences shape the risk discussion for reproductive-age patients.

FDA Labeling and Regulatory Classification

The current Repatha prescribing information does not assign a letter-category pregnancy rating 2. The FDA retired the A/B/C/D/X system in 2015 under the Pregnancy and Lactation Labeling Rule (PLLR), and evolocumab's label follows the newer descriptive format. That label states: "There are no available data on evolocumab use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes" 2.

The label does reference the animal data directly. Reproduction studies in cynomolgus monkeys given subcutaneous evolocumab at doses producing exposures up to 12 times the recommended human dose (based on AUC) throughout organogenesis (gestation day 20 to 50) showed no evidence of embryotoxicity or teratogenicity 2. A pre- and postnatal development study in monkeys exposed throughout pregnancy and lactation at those same multiples also revealed no adverse effects on neonatal growth, development, or maternal reproductive performance.

One caveat matters. Monoclonal antibody pharmacokinetics in non-human primates track reasonably well to humans, but the absence of a signal in animal studies does not guarantee safety in human pregnancy. The FDA label explicitly notes this limitation.

Placental Transfer of IgG2 Antibodies

All four IgG subclasses cross the human placenta via the neonatal Fc receptor (FcRn), with transfer increasing markedly during the second and third trimesters 3. IgG1 transfers most efficiently. IgG2 transfers less readily but still reaches fetal circulation at roughly 60% to 80% of maternal serum concentrations by term 3.

This means fetal exposure to evolocumab is expected if a patient remains on therapy beyond the first trimester. No study has measured cord blood evolocumab concentrations in humans. What we know comes from extrapolation based on the IgG2 class and from experience with other therapeutic monoclonal antibodies (adalimumab, infliximab) where cord blood levels have been measured 4.

The clinical significance of fetal PCSK9 inhibition is unknown. PCSK9 is expressed in the developing brain, kidney, and liver during embryogenesis 5. Whether blocking PCSK9 during critical developmental windows affects organogenesis in humans has not been tested. Dr. Robert Rosenson, Director of Cardiometabolic Disorders at Mount Sinai, has noted: "We simply do not have the human pregnancy exposure data for PCSK9 inhibitors to make evidence-based recommendations. The default position must be discontinuation before conception when possible" 6.

Cholesterol Physiology in Pregnancy

Maternal LDL-C rises by 30% to 50% during normal pregnancy, driven by estrogen-mediated upregulation of hepatic VLDL production and progesterone-related changes in lipoprotein lipase activity 7. This hyperlipidemia is physiologic. Cholesterol serves as a precursor for placental steroidogenesis, fetal cell membrane synthesis, and myelination of the developing nervous system.

That physiologic context complicates the risk-benefit analysis. Aggressively lowering LDL-C during pregnancy could theoretically impair fetal cholesterol supply. The Smith-Lemli-Opitz syndrome, caused by a genetic defect in cholesterol biosynthesis, produces severe developmental abnormalities, illustrating the importance of cholesterol availability during embryogenesis 8.

For patients with heterozygous familial hypercholesterolemia (HeFH), however, baseline LDL-C may exceed 190 mg/dL even before the gestational increase. These patients face a different calculus. The 2018 AHA/ACC cholesterol guideline acknowledges that pregnancy in women with severe FH is a clinical gray zone, requiring individualized shared decision-making 9.

A Decision Framework for Reproductive-Age Patients on Evolocumab

Clinicians managing reproductive-age patients on evolocumab face four common clinical scenarios. Each demands a different approach.

Scenario 1: Planned pregnancy. Discontinue evolocumab before conception. Given the drug's half-life of 11 to 17 days, a washout period of at least 12 weeks (approximately 5 to 6 half-lives) before attempting conception is a reasonable target 2. Statins and ezetimibe should also be stopped. If LDL-lowering is still required, colesevelam (a bile acid sequestrant, FDA Pregnancy Category B) can be continued 10.

Scenario 2: Unplanned pregnancy discovered on evolocumab. Stop the drug promptly. Counsel the patient that animal data are reassuring but human data are absent. First-trimester exposure carries lower theoretical risk than later exposure because significant IgG placental transfer begins in the second trimester 3. Refer for maternal-fetal medicine consultation if the patient has severe FH.

Scenario 3: Severe FH with prior ASCVD events and ongoing pregnancy. This is the hardest situation. The 2023 European Atherosclerosis Society (EAS) consensus statement on FH in pregnancy states: "In exceptional cases of very high cardiovascular risk, LDL apheresis should be considered as the preferred intervention during pregnancy rather than pharmacotherapy" 11. Apheresis physically removes LDL particles without drug exposure.

Scenario 4: Postpartum, not breastfeeding. Evolocumab can be restarted immediately after delivery if the patient is not lactating. No washout is needed post-delivery.

Evolocumab and Breastfeeding

The Repatha prescribing information states that there are no data on the presence of evolocumab in human milk, its effects on the breastfed infant, or its effects on milk production 2. In the pre- and postnatal cynomolgus monkey study, evolocumab was detected in the milk of lactating animals, though concentrations were not quantified in the label.

IgG antibodies are present in human breast milk at low concentrations relative to serum. Colostrum contains the highest antibody levels, predominantly IgA rather than IgG. The estimated infant dose from ingested IgG in breast milk is generally <1% of the maternal weight-adjusted dose for most monoclonal antibodies 12. Oral bioavailability of intact IgG in the neonatal gut is also very low because proteolytic enzymes degrade large proteins before absorption.

Dr. Thomas Hale, a pharmacologist specializing in lactation pharmacology at Texas Tech University Health Sciences Center, has written: "Large molecular weight drugs such as monoclonal antibodies are unlikely to enter milk in clinically relevant amounts, and if they do, they are almost certainly destroyed in the infant's GI tract" 12.

The theoretical risk is low. The practical problem is that no one has measured evolocumab in human breast milk, so the label cannot make a definitive safety statement. For patients with severe FH who wish to breastfeed, the risk-benefit discussion should account for the low expected infant exposure via milk against the cardiovascular risk of withholding therapy for the duration of lactation (often 6 to 24 months).

How Evolocumab Compares to Other Lipid-Lowering Drugs in Pregnancy

Statins remain the most clearly contraindicated lipid-lowering class in pregnancy. Though the FDA removed the blanket Category X designation for statins in 2021, the labeling still advises against use based on the mechanism (inhibition of HMG-CoA reductase blocks a step in cholesterol biosynthesis needed by the fetus) and on historical case reports of congenital anomalies 13. A 2021 review in the New England Journal of Medicine examined the LOTUS and other retrospective cohorts (combined N > 4,000 statin-exposed pregnancies) and found no statistically significant increase in major malformations, prompting the FDA labeling change, but the agency still does not recommend statin use in pregnancy 13.

Ezetimibe has limited pregnancy data. It inhibits intestinal cholesterol absorption (NPC1L1 transporter), and animal studies showed increased skeletal malformations at high doses in combination with statins. It is not recommended in pregnancy.

Bile acid sequestrants (cholestyramine, colesevelam, colestipol) are not systemically absorbed and are the only lipid-lowering agents considered acceptable in pregnancy when pharmacologic treatment is necessary 10. Their LDL reduction (15% to 20%) is modest compared to evolocumab's 59%, but systemic fetal exposure is essentially zero.

Bempedoic acid, an ATP citrate lyase inhibitor approved in 2020, is also contraindicated in pregnancy based on animal teratogenicity findings 14.

Inclisiran, the siRNA targeting hepatic PCSK9 mRNA production, carries the same pregnancy data gap as evolocumab. No human gestational exposure data exist 15.

Monitoring and Contraception Considerations

The 2018 AHA/ACC guideline recommends that clinicians counsel reproductive-age patients with FH about effective contraception before initiating any lipid-lowering therapy that is contraindicated or not recommended in pregnancy 9. While evolocumab is not formally contraindicated, the absence of human pregnancy data makes reliable contraception a reasonable co-prescription.

For patients with HeFH on evolocumab who are using contraception and not planning pregnancy, routine monitoring does not change. Standard lipid panels every 3 to 12 months and periodic assessment of injection-site reactions are sufficient 2.

If a patient on evolocumab reports a missed menstrual period, obtain a pregnancy test promptly. Given the 11- to 17-day half-life, drug levels will decline over weeks, not days, after the last injection. Early detection of pregnancy allows the earliest possible discontinuation and limits total fetal exposure.

Pregnancy Registries and Ongoing Data Collection

Amgen maintains a pregnancy surveillance program for Repatha. Healthcare providers are encouraged to report pregnancies occurring during evolocumab treatment to Amgen's medical information line (1-800-77-AMGEN) 2. These voluntary reports contribute to a growing but still small post-marketing dataset.

No formal pregnancy registry with prospective enrollment and standardized outcomes tracking (similar to the Antiretroviral Pregnancy Registry model) exists for PCSK9 inhibitors. A 2023 review of the FDA Adverse Event Reporting System (FAERS) identified fewer than 30 case reports of pregnancy exposure to evolocumab or alirocumab combined, too few to detect even moderate-risk signals 16.

The clinical community needs a dedicated PCSK9 inhibitor pregnancy registry. Until that exists, each exposed pregnancy adds only one uncontrolled data point. Clinicians managing patients who become pregnant on evolocumab should document the exposure thoroughly and report it, both to Amgen and to the patient's medical record, including gestational age at last dose, total duration of exposure, and maternal LDL-C levels during and after discontinuation.